23andMe, a popular South San Francisco-based genetic testing company, is laying off 40% of its workers after struggling with dismal earnings and a chaotic data breach.

The company is scrapping approximately 200 employees, 23andMe announced in a Monday news release, which is expected to save the business more than $35 million.

It's unclear what exact compensation laid off employees will receive, but 23andMe said it expects to spend approximately $12 million in severance packages and transition and termination costs, according to the release.

A spokesperson for 23andMe told SFGATE that the layoffs will affect workers across the nation, including remote workers, and the severance packages will depend on employees' location and tenure.

California's Employment Development Department has not received a WARN filing yet from the company, Barry White, a spokesperson for the department, told SFGATE.

23andMe is also discontinuing its therapeutic program, which is focused on finding treatments, such as drug developments, for various diseases by studying human genetic data. Though there's no specific timeline for replacing the therapeutic program, the release said, the company will "wind-down its ongoing clinical trials as quickly as practical."

"We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships," said CEO Anne Wojcicki in the news release.

The business restructuring comes after all of 23andMe's independent board directors resigned in September over concerns with the CEO's idea to make the company private and whether a potential buyer could view the personal data of users as an asset to be acquired.

23andMe has been the target of major data breaches, with a hacker acquiring millions of people's information last year. At least 14,000 accounts were compromised during the breach, and the hacker was able to see approximately 6.9 million people's DNA profiles using a "DNA Relative" tool on the program.